Lexeo Therapeutics (LXEO) Other Accumulated Expenses (2022 - 2026)

Lexeo Therapeutics has reported Other Accumulated Expenses for 5 years, with the latest figure at $103000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 84.6% year-over-year to $103000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103000.0 (down 84.6% YoY) and the FY2025 annual result came in at $73000.0, down 86.61% from the prior year.
• Other Accumulated Expenses rose to $103000.0 in Q1 2026 per LXEO's latest filing, from $73000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $669000.0 in Q1 2025 and troughed at $73000.0 in Q4 2025.
• A 5-year average of $306250.0 and a median of $197500.0 in 2025 frame the typical range for Other Accumulated Expenses.
• The widest YoY moves for Other Accumulated Expenses: up 280.11% in 2025, down 86.61% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $240000.0 in 2022, then soared by 130.83% to $554000.0 in 2023, then declined by 1.62% to $545000.0 in 2024, then sank by 86.61% to $73000.0 in 2025, then jumped by 41.1% to $103000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $103000.0, $73000.0, and $209000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.